As per the latest research report, the size of the insulin delivery devices market in the Middle East & Africa region is estimated to be worth USD 910 million by 2027 from USD 700 million in 2022, projecting a CAGR of 5.29% from 2022 to 2027.
Insulin maintains sugar levels in the blood and is essential for people who have type I diabetes & type II diabetes in the Middle East and Africa. Therefore, the development of insulin delivery devices has been encouraged in the past years. These devices are used to deliver insulin doses via the parenteral route rather than the oral route of administration. Insulin delivery devices promote the absorption rate of insulin into the bloodstream from injection to execute immediate pharmacological action of insulin. Some of the majorly used insulin delivery devices include insulin syringes, insulin pens, insulin pen needles, insulin pumps, and insulin jet injectors.
The growing aging population, increasing the incidence rate of diabetes among the population, rising government initiatives towards diabetes, and growing awareness among diabetes patients are factors driving the growth of the insulin delivery devices market in the Middle East and Africa.
However, insufficient healthcare infrastructure to maintain the advanced insulin delivery devices, inadequate number of physicians, and unavailability of social and economic facilities are expected to restrain the growth of the insulin delivery devices market in the Middle East and Africa.
This research report on the MEA Insulin Delivery Devices Market has been segmented and sub-segmented into the following categories:
The MEA Insulin Delivery Devices market is expected to record a considerable share in the global market during the forecast period. Over the recent years, the prevalence of diabetes in people in the Middle East and Africa area has increased dramatically. It is the rise in the prevalence of cardiovascular diseases and obesity that are driving the market growth. However, the growing diabetes population is driving the demand for insulin delivery devices. Presently diabetes had affected over 5.42 million individuals in Saudi Arabia.
South Africa held the largest share of the insulin delivery devices market. The presence of the diabetic population significantly contributing to the insulin market growth. The prevalence of diabetes in South Africa is over 9 percent, with rising in the other problems obesity, healthcare expenditure. Moreover, the growing diabetes population drives the demand for insulin delivery devices.
Furthermore, the counties such as UAE and Saudi Arabia are projected to witness considerable share and contribute to the MEA regional market growth. The market growth is attributed to the growing need for insulin has prompted extensive R&D efforts to develop painless insulin delivery systems, such as CGM-integrated insulin pumps. Earlier syringes were the only way to administer insulin at first, and they were unpleasant and inconvenient to use. Therefore, this feature a fixed dosage form and is less uncomfortable to use; it will also help minimize insulin waste.
KEY MARKET PLAYERS:
Companies like Becton, Dickinson, and Company (U.S.), Sanofi (France), Novo Nordisk A/S (Denmark), Julphar (U.A.E.), Eli Lilly and Company (U.S.), Biocon Ltd. (India), Ypsomed AG (Switzerland), Wockhardt Ltd. (India), B. Braun Meselgen AG (Switzerland) and Biodel Inc. (U.S.) are playing a promising role in the MEA Insulin Delivery Devices Market.
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2000
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: firstname.lastname@example.org